Format

Send to

Choose Destination
Pharmacogenetics. 1998 Jun;8(3):269-81.

Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas.

Author information

1
Division of a Medical Genetics, Harbor-UCLA Medical Centre, Torrance, USA. henry.linhumc.edu

Abstract

N-acetyltransferase NAT1, together with enzymes CYP1A2 and NAT2, helps convert heterocyclic amines to mutagens. Epidemiologic studies of the association of variants of these enzymes with colorectal cancer may provide indirect support for a heterocyclic amine mechanism. We used single strand conformation polymorphism and heteroduplex analysis to screen fro mutations in the NAT1 coding region in a case-control study (n = 932) of colorectal adenomas, which are precursors to cancer. Thirteen different single-base mutations were found: C97T, C190T, T402C, G445A-G459A-T640G ( a combination of three mutations), C559T, G560A, A613G, A752T, T777C, G781A, and A787G. Function of novel mutations was tested by bacterial production of enzymes and measurements of Km, Vmax, and stability. However, on 24-control individuals and 18 cases carried an inactivating NAT1 mutation. When combined with our data on the NAT2 acetylation polymorphism, we saw no evidence for an association between N-acetyltransferases and prevalence of adenomas. Larger sample sizes are required for further evaluation.

PMID:
9682272
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center